Mylan acquiring Aspen’s European thrombosis business

Mylan is expanding its complex injectables offering and presence in hospitals with the €641.9 million acquisition of Aspen Pharmacare’s thrombosis business in Europe.

The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

These products had combined net sales of approximately €231 million for the 12 months ended June 30, 2020.

“The acquisition of this thrombosis portfolio is a significant addition to Mylan’s European business that will not only make Mylan the second largest supplier of these products to patients in Europe, according to IQVIA, but also bolster our existing commercial infrastructure to further expand access to complex injectables,” said Mylan President Rajiv Malik.

“By adding to our highly experienced sales and marketing team, we will further strengthen our current reach in hospitals and enhance the future growth of our biosimilars franchise in Europe.”

The acquisition is expected to be accretive to Viatris – the merger between Mylan and Pfizer’s Upjohn.

“As we continue toward the launch of  Viatris, we remain committed to executing on opportunities that will not only add to Mylan’s growth, but that also will be consistent with our vision for Viatris under the Global Healthcare Gateway, which we believe will establish the new company as a true Partner of Choice,” said Mylan Executive Chairman Robert J. Coury.

Aspen will retain manufacturing and product supply responsibilities and will supply Mylan with finished product. Aspen has a fully vertically integrated supply chain predominantly located in Europe.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...

Moderna regains rights to RSV vaccine from Merck

Moderna has regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. mRNA-1172,...

Takeda & Arrowhead to co-develop RNAi therapy for AATLD

Takeda and Arrowhead Pharmaceuticals will collaborate to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver...

Related news

CHMP recommends ViiV’s long-acting regimen for HIV

The Committee for Medicinal Products for Human Use (CHMP) has recommended ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in combination with Rekambys (rilpivirine injection)...

4D pharma merges with SPAC in $37.6m deal

4D pharma, the listed Leeds-headquartered pharmaceutical company, has merged with Longevity, a special purpose acquisition company (SPAC), in a deal worth up to $37.6...

Cyted acquires Pathognomics Ltd to support expansion of digital pathology and diagnostic reporting services

Cyted Ltd, a developer and provider of artificial intelligence technology and digital diagnostic infrastructure to enable earlier detection of disease, has acquired Pathognomics Limited,...

Record quarter for UK biotech as £1bn is raised

UK biotech companies raised more than £1 billion in equity finance between June and August 2020, the highest quarter for investments in the sector...